# EDGAR Filing Document

**Accession Number:** 0000946644
**File Stem:** 0001493152-25-020102
**Filing Date:** 2025-10
**Character Count:** 8570
**Document Hash:** 3676498c4becde5d019cb40304d907fe
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-020102.hdr.sgml**: 20251029

**ACCESSION NUMBER**: 0001493152-25-020102

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 204

**CONFORMED PERIOD OF REPORT**: 20251029

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251029

**DATE AS OF CHANGE**: 20251029

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AIM ImmunoTech Inc.
- **CENTRAL INDEX KEY:** 0000946644
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 520845822
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-27072
- **FILM NUMBER:** 251430978

**BUSINESS ADDRESS:**
- **STREET 1:** 2117 SW HIGHWAY 484
- **CITY:** OCALA
- **STATE:** FL
- **ZIP:** 32801
- **BUSINESS PHONE:** 352-448-7797

**MAIL ADDRESS:**
- **STREET 1:** 2117 SW HIGHWAY 484
- **CITY:** OCALA
- **STATE:** FL
- **ZIP:** 32801

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HEMISPHERX BIOPHARMA INC
- **DATE OF NAME CHANGE:** 19950614

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The**

**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported) October 29, 2025**

**AIM IMMUNOTECH INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-27072** | **52-0845822** |
| (state or other jurisdiction | (Commission | (IRS Employer |
| of incorporation) | File Number) | Identification No.) |

---

---

| | |
|:---|:---|
| **2117 SW Highway 484, Ocala FL** | **34473** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: (352) 448-7797

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| Title of each class | Name of each exchange on which registered |
| Common Stock, par value $0.001 per share AIM | NYSE American |

---

**Item 1.01 Entry into a Material Definitive Agreement**

Filed herewith as Exhibit 3.1(i) is the Company's Certificate of Incorporation as amended and restated through the date here. Exhibit 3.1(i) supersedes all individual Exhibits that contain pieces thereof.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

The following exhibits are filed herewith:

---

| | |
|:---|:---|
| Exhibit |  |
| Number | Description |
| 3.1(i). | [The Company's Certificate of Incorporation as amended and restated through October 29, 2025](ex3-1_i.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**<u>SIGNATURES</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | AIM ImmunoTech Inc. | AIM ImmunoTech Inc. |
| Date: | October 29, 2025 | By | */s/ Thomas K. Equels* |
| | |  | Thomas K. Equels, CEO |

---

## Exhibit 3.1

**Exhibit 3.1(i)**

![](ex3-1i_001.jpg)

![](ex3-1i_002.jpg)

![](ex3-1i_003.jpg)

![](ex3-1i_004.jpg)

![](ex3-1i_005.jpg)

![](ex3-1i_006.jpg)

![](ex3-1i_007.jpg)

![](ex3-1i_008.jpg)

![](ex3-1i_009.jpg)

![](ex3-1i_010.jpg)

![](ex3-1i_011.jpg)

![](ex3-1i_012.jpg)

![](ex3-1i_013.jpg)

![](ex3-1i_014.jpg)

![](ex3-1i_015.jpg)

![](ex3-1i_016.jpg)

![](ex3-1i_017.jpg)

![](ex3-1i_018.jpg)

![](ex3-1i_019.jpg)

![](ex3-1i_020.jpg)

![](ex3-1i_021.jpg)

![](ex3-1i_022.jpg)

![](ex3-1i_023.jpg)

![](ex3-1i_024.jpg)

![](ex3-1i_025.jpg)

![](ex3-1i_026.jpg)

![](ex3-1i_027.jpg)

![](ex3-1i_028.jpg)

![](ex3-1i_029.jpg)

![](ex3-1i_030.jpg)

![](ex3-1i_031.jpg)

![](ex3-1i_032.jpg)

![](ex3-1i_033.jpg)

![](ex3-1i_034.jpg)

![](ex3-1i_035.jpg)

![](ex3-1i_036.jpg)

![](ex3-1i_037.jpg)

![](ex3-1i_038.jpg)

![](ex3-1i_039.jpg)

![](ex3-1i_040.jpg)

![](ex3-1i_041.jpg)

![](ex3-1i_042.jpg)

![](ex3-1i_043.jpg)

![](ex3-1i_044.jpg)

![](ex3-1i_045.jpg)

![](ex3-1i_046.jpg)

![](ex3-1i_047.jpg)

![](ex3-1i_048.jpg)

![](ex3-1i_049.jpg)

![](ex3-1i_050.jpg)

![](ex3-1i_051.jpg)

![](ex3-1i_052.jpg)

![](ex3-1i_053.jpg)

![](ex3-1i_054.jpg)

![](ex3-1i_055.jpg)

![](ex3-1i_056.jpg)

![](ex3-1i_057.jpg)

![](ex3-1i_058.jpg)

![](ex3-1i_059.jpg)

![](ex3-1i_060.jpg)

![](ex3-1i_061.jpg)

![](ex3-1i_062.jpg)

![](ex3-1i_063.jpg)

![](ex3-1i_064.jpg)

![](ex3-1i_065.jpg)

![](ex3-1i_066.jpg)

![](ex3-1i_067.jpg)

![](ex3-1i_068.jpg)

![](ex3-1i_069.jpg)

![](ex3-1i_070.jpg)

![](ex3-1i_071.jpg)

![](ex3-1i_072.jpg)

![](ex3-1i_073.jpg)

![](ex3-1i_074.jpg)

![](ex3-1i_075.jpg)

![](ex3-1i_076.jpg)

![](ex3-1i_077.jpg)

![](ex3-1i_078.jpg)

![](ex3-1i_079.jpg)

![](ex3-1i_080.jpg)

![](ex3-1i_081.jpg)

![](ex3-1i_082.jpg)

![](ex3-1i_083.jpg)

![](ex3-1i_084.jpg)

![](ex3-1i_085.jpg)

![](ex3-1i_086.jpg)

![](ex3-1i_087.jpg)

![](ex3-1i_088.jpg)

![](ex3-1i_089.jpg)

![](ex3-1i_090.jpg)

![](ex3-1i_091.jpg)

![](ex3-1i_092.jpg)

![](ex3-1i_093.jpg)

![](ex3-1i_094.jpg)

![](ex3-1i_095.jpg)

![](ex3-1i_096.jpg)

![](ex3-1i_097.jpg)

![](ex3-1i_098.jpg)

![](ex3-1i_099.jpg)

![](ex3-1i_100.jpg)

![](ex3-1i_101.jpg)

![](ex3-1i_102.jpg)

![](ex3-1i_103.jpg)

![](ex3-1i_104.jpg)

![](ex3-1i_105.jpg)

![](ex3-1i_106.jpg)

![](ex3-1i_107.jpg)

![](ex3-1i_108.jpg)

![](ex3-1i_109.jpg)

![](ex3-1i_110.jpg)

![](ex3-1i_111.jpg)

![](ex3-1i_112.jpg)

![](ex3-1i_113.jpg)

![](ex3-1i_114.jpg)

![](ex3-1i_115.jpg)

![](ex3-1i_116.jpg)

![](ex3-1i_117.jpg)

![](ex3-1i_118.jpg)

![](ex3-1i_119.jpg)

![](ex3-1i_120.jpg)

![](ex3-1i_121.jpg)

![](ex3-1i_122.jpg)

![](ex3-1i_123.jpg)

![](ex3-1i_124.jpg)

![](ex3-1i_125.jpg)

![](ex3-1i_126.jpg)

![](ex3-1i_127.jpg)

![](ex3-1i_128.jpg)

![](ex3-1i_129.jpg)

![](ex3-1i_130.jpg)

![](ex3-1i_131.jpg)

![](ex3-1i_132.jpg)

![](ex3-1i_133.jpg)

![](ex3-1i_134.jpg)

![](ex3-1i_135.jpg)

![](ex3-1i_136.jpg)

![](ex3-1i_137.jpg)

![](ex3-1i_138.jpg)

![](ex3-1i_139.jpg)

![](ex3-1i_140.jpg)

![](ex3-1i_141.jpg)

![](ex3-1i_142.jpg)

![](ex3-1i_143.jpg)

![](ex3-1i_144.jpg)

![](ex3-1i_145.jpg)

![](ex3-1i_146.jpg)

![](ex3-1i_147.jpg)

![](ex3-1i_148.jpg)

![](ex3-1i_149.jpg)

![](ex3-1i_150.jpg)

![](ex3-1i_151.jpg)

![](ex3-1i_152.jpg)

![](ex3-1i_153.jpg)

![](ex3-1i_154.jpg)

![](ex3-1i_155.jpg)

![](ex3-1i_156.jpg)

![](ex3-1i_157.jpg)

![](ex3-1i_158.jpg)

![](ex3-1i_159.jpg)

![](ex3-1i_160.jpg)

![](ex3-1i_161.jpg)

![](ex3-1i_162.jpg)

![](ex3-1i_163.jpg)

![](ex3-1i_164.jpg)

![](ex3-1i_165.jpg)

![](ex3-1i_166.jpg)

![](ex3-1i_167.jpg)

![](ex3-1i_168.jpg)

![](ex3-1i_169.jpg)

![](ex3-1i_170.jpg)

![](ex3-1i_171.jpg)

![](ex3-1i_172.jpg)

![](ex3-1i_173.jpg)

![](ex3-1i_174.jpg)

![](ex3-1i_175.jpg)

![](ex3-1i_176.jpg)

![](ex3-1i_177.jpg)

![](ex3-1i_178.jpg)

![](ex3-1i_179.jpg)

![](ex3-1i_180.jpg)

![](ex3-1i_181.jpg)

![](ex3-1i_182.jpg)

![](ex3-1i_183.jpg)

![](ex3-1i_184.jpg)

![](ex3-1i_185.jpg)

![](ex3-1i_186.jpg)

![](ex3-1i_187.jpg)

![](ex3-1i_188.jpg)

![](ex3-1i_189.jpg)

![](ex3-1i_190.jpg)

![](ex3-1i_191.jpg)